Circulating carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels were regularly quantified to monitor the inhibition and growth of the pancreatic cancer (Figure 1). This evidence concerns the gene CEACAM5 and pancreatic neoplasm.